← United States · Coverage record
US · SEC FORM 4
AVENUE THERAPEUTICS, INC.
ATXI · OTC · CIK 0001644963 · Healthcare · Biotechnology
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
0 Form 4 transaction lines observed in the same window
0 sales · 0 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Insider activity timeline
No Form 4 transaction event is present in the current 180-day window.
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2024-09-30 · KRANZLER JAY D.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.
Price performance
- 1M
- -34.1%
- 3M
- +34.8%
- 6M
- -4.5%
- 12M
- -42.5%
Volatility & liquidity
- Volatility
- 199.9%
- Beta
- —
- Avg daily value
- USD 2,835
Valuation
- Market cap
- USD 1.4M
- P/E
- —
Fundamentals
- Profit margin
- -207.2%
- ROE
- -158.8%
- Industry
- Biotechnology
Market data
Price data up to: 2026-10-09 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, Profit margin, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-04 · Status: PASS
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 1
- Previous report
- 1,329
- Avg daily volume
- 9,857
- Days to cover
- ≤ 1.0
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2024-09-30 | KRANZLER JAY D | Purchase (P) | COMMON STOCK, PAR VALUE $0.0001 | 497 | USD 2.50 | USD 1,242 | SEC filing ↗ |
| 2024-09-27 | KRANZLER JAY D | Purchase (P) | COMMON STOCK, PAR VALUE $0.0001 | 3 | USD 2.40 | USD 7 | SEC filing ↗ |
| 2023-09-08 | ROSENWALD LINDSAY A MD | Purchase (P) | Common Stock | 348,675 | USD 0.72 | USD 251,046 | SEC filing ↗ |
| 2023-09-08 | Fortress Biotech, Inc. | Purchase (P) | Common Stock | 418,410 | USD 0.72 | USD 301,255 | SEC filing ↗ |
| 2021-05-06 | Herskowitz Neil | Purchase (P) | Common Stock | 2,500 | USD 3.99 | USD 9,975 | SEC filing ↗ |
| 2020-03-10 | Vazzano Joseph Walter | Purchase (P) | Common Stock | 1,889 | USD 7.94 | USD 14,999 | SEC filing ↗ |
| 2020-03-09 | Vazzano Joseph Walter | Purchase (P) | Common Stock | 1,500 | USD 7.99 | USD 11,983 | SEC filing ↗ |
| 2020-02-27 | Herskowitz Neil | Purchase (P) | Common Stock | 2,400 | USD 8.20 | USD 19,680 | SEC filing ↗ |
| 2020-02-26 | Herskowitz Neil | Purchase (P) | Common Stock | 161 | USD 8.73 | USD 1,406 | SEC filing ↗ |
| 2020-02-25 | Vazzano Joseph Walter | Purchase (P) | Common Stock | 1,200 | USD 9.09 | USD 10,908 | SEC filing ↗ |
| 2020-02-25 | Herskowitz Neil | Purchase (P) | Common Stock | 10,000 | USD 9.31 | USD 93,100 | SEC filing ↗ |
Form 4 evidence
1 transaction lines in the latest 365-day window; 41 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-01-02 | Fortress Biotech, Inc. | Award / grant (A) | COMMON STOCK, PAR VALUE $0.0001 | 111,209 | USD 0.00 | USD 0 | SEC filing ↗ |
Show recent Form 4 evidence (1 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-01-02 | Fortress Biotech, Inc. | Award / grant (A) | COMMON STOCK, PAR VALUE $0.0001 | 111,209 | USD 0.00 | USD 0 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | ATXI |
| CIK | 0001644963 |
| Sector | Healthcare |
| Industry | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| Exchange | OTC |
Data coverage
| Local Form 4 history | 41 transaction lines from 2020-02-25 to 2026-01-02 12 P purchase lines · 11 S sale lines · 18 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.